Oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 11.1% year on year to $186.7 million. The company expects the full year’s revenue to be around $800 million, close to analysts’ estimates. Its non-GAAP profit of $0.01 per share was in line with analysts’ consensus estimates.
Is now the time to buy NEO? Find out in our full research report (it’s free for active Edge members).
NeoGenomics (NEO) Q1 CY2026 Highlights:
- Revenue: $186.7 million vs analyst estimates of $184.5 million (11.1% year-on-year growth, 1.2% beat)
- Adjusted EPS: $0.01 vs analyst estimates of $0 (in line)
- Adjusted EBITDA: $9.00 million vs analyst estimates of $8.33 million (4.8% margin, 8% beat)
- The company slightly lifted its revenue guidance for the full year to $800 million at the midpoint from $797 million
- EBITDA guidance for the full year is $56 million at the midpoint, in line with analyst expectations
- Operating Margin: -9.8%, up from -16.6% in the same quarter last year
- Market Capitalization: $1.17 billion
StockStory’s Take
NeoGenomics delivered an 11% year-over-year revenue increase in Q1, exceeding Wall Street’s expectations for the period. Management attributed this performance to broad-based growth across clinical testing, led by robust expansion in next-generation sequencing (NGS) and continued progress in shifting the portfolio toward higher-value diagnostics. CEO Anthony Zook noted, “Our clinical business continued its robust growth with revenue increasing 14% year-over-year,” highlighting the company’s focus on commercial execution and product mix improvements in the oncology diagnostics market.
Looking forward, NeoGenomics’ outlook is shaped by the ramp-up of recently launched products, particularly RaDaR ST for molecular residual disease (MRD) testing and the PanTracer liquid biopsy platform. Management emphasized that advancing reimbursement coverage, expanding the sales force, and further penetration of new test indications are core priorities for sustaining growth. CFO Abhishek Jain stated, “We continue to expect gross margin expansion of approximately 100 basis points year-over-year in 2026, driven by our Lab of the Future initiatives,” signaling a focus on both top-line expansion and operational efficiency.
Key Insights from Management’s Remarks
Management highlighted strong NGS adoption, success with new product launches, and targeted investments as the primary drivers of growth and improved business mix in the quarter.
- NGS momentum and mix shift: The company’s next-generation sequencing portfolio, including five products launched in 2023, contributed 25% of clinical revenue in Q1. NGS revenue grew 26% year-over-year, significantly outpacing overall market growth and now represents one-third of clinical revenue. This shift to higher-value testing supported both revenue and average unit price (AUP) gains.
- Product innovation and launches: The full commercial launch of RaDaR ST, NeoGenomics’ circulating tumor DNA assay for MRD detection, marked a major portfolio expansion. Early adoption trends have been positive, with about 29% of previous RaDaR users ordering the new test and a high proportion of RaDaR ST orders bundled with additional NeoGenomics assays.
- PanTracer Liquid reimbursement and impact: The company secured MolDX (Medicare Molecular Diagnostic Services Program) reimbursement for PanTracer Liquid, a noninvasive blood-based test for solid tumors, in March. Management expects this to drive revenue ramp throughout the year and accelerate adoption in the therapy selection vertical.
- Sales force and commercial strategy: NeoGenomics is expanding its sales team, aiming to add approximately 25 new resources by the third quarter to support RaDaR ST and PanTracer growth, particularly as new indications receive reimbursement and product awareness builds in the community oncology setting.
- Operational efficiency and cost actions: The integration of Pathline, expansion of digital interfaces like Epic Aura, and ongoing lab automation initiatives are supporting faster test turnaround times, improved customer workflows, and enhanced operating leverage, contributing to margin improvement and scalability.
Drivers of Future Performance
Management expects new product adoption, expanded reimbursement, and operational improvements to be the main drivers of growth and margin improvement in the coming quarters.
- New test ramp and reimbursement: Revenue growth is expected to be driven by increased adoption of recently launched products, especially as RaDaR ST and PanTracer Liquid gain additional reimbursement indications under MolDX. If approvals for new cancer types are secured, the addressable MRD market could double, supporting sustained top-line momentum.
- Sales force expansion and commercial reach: The planned addition of sales resources is intended to accelerate penetration in key markets, particularly for advanced cancer diagnostics. Management believes this investment will support share gains and higher test volumes across both NGS and MRD offerings.
- Margin expansion initiatives: Ongoing efforts in lab automation, digital pathology, and strategic sourcing are expected to drive approximately 100 basis points of gross margin expansion in 2026. Management cited the “Lab of the Future” initiative as key to improving efficiency and offsetting headwinds from higher freight costs and new product launches.
Catalysts in Upcoming Quarters
In the upcoming quarters, the StockStory team will be closely monitoring (1) the pace of adoption and reimbursement for RaDaR ST and PanTracer Liquid in new cancer indications, (2) the effectiveness of the expanded sales force in driving volume and market penetration, and (3) the progress of lab automation and digital initiatives in supporting gross margin improvement. Additional signs of success will include increased uptake from Epic Aura integrations and stabilization in the nonclinical business.
NeoGenomics currently trades at $9.05, in line with $9.02 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
